Thursday, 12 April 2018
Urinary Catheters Diagnosis, treatments and Global Key players 2017
Summary
The report provides comprehensive information on the pipeline
products with comparative analysis of the products at various stages of
development. The report reviews major players involved in the pipeline product
development. It also provides information about clinical trials in progress,
which includes trial phase, trial status, trial start and end dates, and, the
number of trials for the key Urinary Catheters pipeline products.
This report is prepared using data sourced from in-house
databases, secondary and primary research by team of industry experts.
Click here
for sample report @ http://www.wiseguyreports.com/sample-request/1579706-urinary-catheters-medical-devices-pipeline-assessment-2017
Scope of
The Report
- Extensive coverage of the Urinary Catheters under
development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Urinary Catheters and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Urinary Catheters and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Urinary Catheters Overview 8
3 Products under Development 9
3.1 Urinary Catheters - Pipeline Products by Stage of Development 9
3.2 Urinary Catheters - Pipeline Products by Segment 10
3.3 Urinary Catheters - Pipeline Products by Territory 11
3.4 Urinary Catheters - Pipeline Products by Regulatory Path 12
3.5 Urinary Catheters - Pipeline Products by Estimated Approval Date 13
4 Urinary Catheters - Pipeline Products under Development by Companies 14
4.1 Urinary Catheters Companies - Pipeline Products by Stage of Development 14
4.2 Urinary Catheters - Pipeline Products by Stage of Development 15
5 Urinary Catheters Companies and Product Overview 16
5.1 Applied Catheter Technologies Inc. Company Overview 16
5.1.1 Applied Catheter Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Urinary Catheters Overview 8
3 Products under Development 9
3.1 Urinary Catheters - Pipeline Products by Stage of Development 9
3.2 Urinary Catheters - Pipeline Products by Segment 10
3.3 Urinary Catheters - Pipeline Products by Territory 11
3.4 Urinary Catheters - Pipeline Products by Regulatory Path 12
3.5 Urinary Catheters - Pipeline Products by Estimated Approval Date 13
4 Urinary Catheters - Pipeline Products under Development by Companies 14
4.1 Urinary Catheters Companies - Pipeline Products by Stage of Development 14
4.2 Urinary Catheters - Pipeline Products by Stage of Development 15
5 Urinary Catheters Companies and Product Overview 16
5.1 Applied Catheter Technologies Inc. Company Overview 16
5.1.1 Applied Catheter Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 16
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579706-urinary-catheters-medical-devices-pipeline-assessment-2017
About Us
Wise Guy
Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium
progressive statistical surveying, market research reports, analysis &
forecast data for industries and governments around the globe. Wise Guy Reports
understand how essential statistical surveying information is for your
organization or association. Therefore, we have associated with the top
publishers and research firms all specialized in specific domains, ensuring you
will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner
Relations & Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208
133 9349 (UK)
Chicken Pox Global Market by Treatments, Causes, Drugs and Diet 2017-2022
Chicken Pox
Summary
Clinical trial report, “Chicken Pox Global Clinical Trials Review, H1, 2017" provides an overview of Chicken Pox clinical trials scenario. This report provides top line data relating to the clinical trials on Chicken Pox. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579700-chicken-pox-global-clinical-trials-review-h1-2017
Scope of The Report
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Chicken Pox to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Chicken Pox to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579700-chicken-pox-global-clinical-trials-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
Clinical trial report, “Chicken Pox Global Clinical Trials Review, H1, 2017" provides an overview of Chicken Pox clinical trials scenario. This report provides top line data relating to the clinical trials on Chicken Pox. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579700-chicken-pox-global-clinical-trials-review-h1-2017
Scope of The Report
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Chicken Pox to Infectious Disease Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Chicken Pox to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579700-chicken-pox-global-clinical-trials-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
ICT Investment Trends in Germany - Granular Market Report and Review, 2017
ICT Investment Trends in Germany
Summary
German enterprises are investing in various ICT domains in order to introduce pioneering digital services in the future. Germany's economy is growing firmly in 2017, and had a huge trade surplus in 2016, with high exports in vehicles, machinery, pharmaceuticals, and electrical equipment, which are pushing investments in the ICT sector. Software as a service (SaaS) was the most popular cloud computing solution in 2016, infrastructure as a service (IaaS) is also set to gain momentum in the next two years, driven by the need to achieve flexibility and scalability in their architecture for creating an on-demand infrastructure extension or scaling down without difficulty.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579654-ict-investment-trends-in-germany-maintaining-data-privacy-and-security-is
Scope of The Report
- The survey shows that German enterprises are looking to increase their total ICT budget in 2017, indicating that enterprises are moving towards technology driven work environments to boost productivity.
- As the German government is focussing on helping small and medium-sized enterprises (SMEs) to digitally transform their businesses under its ‘Digital Strategy 2025’ plan, local software vendors and network providers are expected to attract greater opportunities in the SME market.
- Increasing customer satisfaction tops the list of business objectives, followed by the need to gain a competitive advantage, in influencing IT investment strategies among German enterprises.
Table of Contents
Table of Contents
Key findings
Key implications for ICT vendors
Executive summary
Survey demographics
ICT budget changes
ICT budget allocation by core technology area
Hardware budget breakdown
Software budget breakdown
Third party IT services expenditure
Communications expenditure
Cloud computing budget
ICT budget allocation by function
Outsourced IT functions
ICT investment priorities and vendor satisfaction
Enterprise applications
Internet of Things (IoT)
Cloud computing
Business intelligence
Business objectives influencing IT investment strategy
ICT provider selection
Key decision makers for purchasing technology
Appendix
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579654-ict-investment-trends-in-germany-maintaining-data-privacy-and-security-is
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
German enterprises are investing in various ICT domains in order to introduce pioneering digital services in the future. Germany's economy is growing firmly in 2017, and had a huge trade surplus in 2016, with high exports in vehicles, machinery, pharmaceuticals, and electrical equipment, which are pushing investments in the ICT sector. Software as a service (SaaS) was the most popular cloud computing solution in 2016, infrastructure as a service (IaaS) is also set to gain momentum in the next two years, driven by the need to achieve flexibility and scalability in their architecture for creating an on-demand infrastructure extension or scaling down without difficulty.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579654-ict-investment-trends-in-germany-maintaining-data-privacy-and-security-is
Scope of The Report
- The survey shows that German enterprises are looking to increase their total ICT budget in 2017, indicating that enterprises are moving towards technology driven work environments to boost productivity.
- As the German government is focussing on helping small and medium-sized enterprises (SMEs) to digitally transform their businesses under its ‘Digital Strategy 2025’ plan, local software vendors and network providers are expected to attract greater opportunities in the SME market.
- Increasing customer satisfaction tops the list of business objectives, followed by the need to gain a competitive advantage, in influencing IT investment strategies among German enterprises.
Table of Contents
Table of Contents
Key findings
Key implications for ICT vendors
Executive summary
Survey demographics
ICT budget changes
ICT budget allocation by core technology area
Hardware budget breakdown
Software budget breakdown
Third party IT services expenditure
Communications expenditure
Cloud computing budget
ICT budget allocation by function
Outsourced IT functions
ICT investment priorities and vendor satisfaction
Enterprise applications
Internet of Things (IoT)
Cloud computing
Business intelligence
Business objectives influencing IT investment strategy
ICT provider selection
Key decision makers for purchasing technology
Appendix
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579654-ict-investment-trends-in-germany-maintaining-data-privacy-and-security-is
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
The Baby Food Market - Granular Market Report and Review, H1 2017
The Baby Food Market
Summary
The Chinese market for baby food rose by 23% between 2010 and 2016 in terms volume, but fell for the first time in recent years in 2016. Although the market is still underdeveloped, it has benefited from greater consumer spending power, the rising levels of urbanization and increased numbers of working women. Consumption increased in all sectors except drinks, although in value terms baby milks made the greatest gains, rising by 79% between 2010 and 2016. Baby milks continue to dominate the market, accounting for over 92% of value and 86% of volume sales. Much of the remainder is made up of cereals & dry meals, wet meals claim 2-3% of value sales, with finger foods and drinks together taking less than 1% of value sales. In coming years, once regulatory changes have concluded - sales are expected to be boosted by the expansion of distribution and by rising incomes. The overall market is forecast to increase by 26% in volume and 51% in value between 2016 and 2022.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579596-the-baby-food-market-in-china-2017
Scope of The Report
- Consumption of baby food in China rose by 23% since 2010 in terms of volume. Market value rose by 78% between 2010 and 2016.
- The bulk of baby food sales continue to occur in the major cities, although increasingly affluent consumers are emerging in second-, third-, and even fourth-tier cities, as well as the better-off parts of the rural community.
- The Chinese infant formula market is the world’s largest; now well ahead of both the US and the total market in Western Europe.
- The market is highly fragmented with a large number of foreign and local manufacturers active.
- The majority of milks are now imported, due to strong consumer preference for imported products, but most cereals, meals, and other products are produced locally.
Table of Contents
Table of Contents
Introduction
Background to the Market
Market Overview
Sector Analysis
Production and Trade
Company Profiles
Distribution
Economic Background
Prospects and Forecasts
Appendix
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579596-the-baby-food-market-in-china-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
The Chinese market for baby food rose by 23% between 2010 and 2016 in terms volume, but fell for the first time in recent years in 2016. Although the market is still underdeveloped, it has benefited from greater consumer spending power, the rising levels of urbanization and increased numbers of working women. Consumption increased in all sectors except drinks, although in value terms baby milks made the greatest gains, rising by 79% between 2010 and 2016. Baby milks continue to dominate the market, accounting for over 92% of value and 86% of volume sales. Much of the remainder is made up of cereals & dry meals, wet meals claim 2-3% of value sales, with finger foods and drinks together taking less than 1% of value sales. In coming years, once regulatory changes have concluded - sales are expected to be boosted by the expansion of distribution and by rising incomes. The overall market is forecast to increase by 26% in volume and 51% in value between 2016 and 2022.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1579596-the-baby-food-market-in-china-2017
Scope of The Report
- Consumption of baby food in China rose by 23% since 2010 in terms of volume. Market value rose by 78% between 2010 and 2016.
- The bulk of baby food sales continue to occur in the major cities, although increasingly affluent consumers are emerging in second-, third-, and even fourth-tier cities, as well as the better-off parts of the rural community.
- The Chinese infant formula market is the world’s largest; now well ahead of both the US and the total market in Western Europe.
- The market is highly fragmented with a large number of foreign and local manufacturers active.
- The majority of milks are now imported, due to strong consumer preference for imported products, but most cereals, meals, and other products are produced locally.
Table of Contents
Table of Contents
Introduction
Background to the Market
Market Overview
Sector Analysis
Production and Trade
Company Profiles
Distribution
Economic Background
Prospects and Forecasts
Appendix
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1579596-the-baby-food-market-in-china-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Latest Study Offers Detailed Insights on Neurofibromatoses Type I H1 2017
Neurofibromatoses Type I
Summary
Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Array BioPharma Inc .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Array BioPharma Inc .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Usher Syndrome Assessment and Therapeutics Analysis Forecasts To H1 2017
Usher Syndrome
Summary
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510559-usher-syndrome-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Usher Syndrome - Overview
Usher Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Usher Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Usher Syndrome - Companies Involved in Therapeutics Development
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
Sanofi
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510559-usher-syndrome-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510559-usher-syndrome-pipeline-review-h1-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Usher Syndrome - Overview
Usher Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Usher Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Usher Syndrome - Companies Involved in Therapeutics Development
Amgen Inc
Editas Medicine Inc
ProQR Therapeutics NV
Sanofi
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510559-usher-syndrome-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Subscribe to:
Posts (Atom)